-
Uncategorized2 weeks ago
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
-
Uncategorized2 weeks ago
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance III, could target companies abroad,...
-
Uncategorized2 weeks agoTwelve startups to showcase at SLAS Europe 2026
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition,...
-
Uncategorized2 weeks ago
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a...
-
Uncategorized2 weeks agoLilly’s triple agonist significantly reduces A1C and weight
Eli Lilly has announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1...
-
Uncategorized2 weeks agoStudy supports Treg enhancement as dementia treatment
A research study led by Dr Alireza Faridar and Dr Stanley Appel at the Houston Methodist Neurological Institute has demonstrated the involvement of the peripheral immune...
-
Uncategorized2 weeks ago
Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape
Overall, the top 16 largest pharmaceutical companies spent $159 billion on research and development in 2025, compared to $165 billion the year prior. Here’s where all...
-
Uncategorized2 weeks ago
Trace Unites ALS Teams Behind a Target That Could Broaden Treatment Access
Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims to bring more treatment options to...
-
Uncategorized2 weeks ago
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors....
-
Uncategorized2 weeks agoThe next generation of CAR-T cell therapies
Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space. ...
BioNTech to shutter Singapore HQ after ‘comprehensive review’
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
